NPPB and cancer: Increased cumulative anthracycline dose during cancer treatment was the only independent predictor for any cardiovascular abnormality (decreased exercise capacity or elevated NTproBNP or evidence of diastolic dysfunction) after elimination of influencing factors, such as oncologic diagnosis, gender, age at diagnosis, age at follow-up, follow-up time or exposure to irradiation, on multivariate logistic regression analysis (p = 0.036).